Skip to main
RNTX

RNTX Stock Forecast & Price Target

RNTX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rein Therapeutics Inc is positioned favorably due to its focus on developing therapies for orphan pulmonary and fibrosis indications, highlighted by its promising Phase 2-ready clinical assets. The company’s clinical trials, particularly for LTI-03 and LTI-01, have demonstrated positive safety and biomarker activity results, which support the potential effectiveness of its treatments in markets with limited competition and inadequate existing therapies. Additionally, a favorable risk-reward opportunity exists for investors, contingent on the company's ability to extend its cash runway, enhancing the appeal of its innovative pipeline set to address substantial unmet medical needs.

Bears say

Rein Therapeutics Inc has experienced a significant decline in its stock value, falling 50% year-to-date in 2025, compared to a mere 3.5% drop in the XBI index, primarily due to a halt in patient enrollment for trials in the U.S. This pause in enrollment has generated considerable uncertainty regarding the company's clinical progression and potential market trajectory. Additionally, concerning data has emerged, indicating that lower sRAGE levels are associated with poor survival outcomes in patients with Idiopathic Pulmonary Fibrosis, which may negatively impact the perceived efficacy and development viability of the company's lead product candidate, LTI-03.

RNTX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rein Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rein Therapeutics Inc (RNTX) Forecast

Analysts have given RNTX a Strong Buy based on their latest research and market trends.

According to 1 analysts, RNTX has a Strong Buy consensus rating as of Mar 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rein Therapeutics Inc (RNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.